Prihoda Be-Fr-Ch | Textile Ducting And Diffusers

Prihoda Be-Fr-Ch | Textile Ducting And Diffusers company information, Employees & Contact Information

Prihoda BE-FR-CH is the exclusive partner in Belgium, Luxembourg, France and Switzerland for the 100% made-to-measure textile diffusers from European manufacturer - and international market leader - Prihoda Fabric Ducting. Prihoda textile ducts are used in all types of non-residential HVAC projects: heating, cooling, ventilation, etc. They are lightweight, made-to-measure, easy to install and, above all, much cheaper than metal air ducts. Prihoda supplies tailor-made air distribution systems for optimum air distribution in various rooms, buildings and temporary structures. Our ambition is to be the HVAC/R installer's best partner with tailor-made solutions for industrial and commercial HVAC projects aimed at achieving a perfect and pleasant climate (cooling, heating, ventilation). The Prihoda BE-FR-CH head office is located in Kuurne near Kortrijk. There are local sales offices in France and Switzerland. Contact our team of experts and find out how we can help you with your HVAC project! -------------------------------------------- PRIHODA DUCTS & DIFFUSERS Prihoda airsocks are low-maintenance, 100% high-performance, made-to-measure textile air ducts suitable for heating, cooling and air-conditioning. They are very quick to (dis)assemble in any circumstances and can be perfectly integrated into existing structures or temporary constructions. For greater energy efficiency and guaranteed draught-free operation, both for cooling and heating, membrane ducts can be used. Advantages of Prihoda textile ducts: - Air movement can be adjusted to suit customer requirements - Lightweight; less than 5% of the weight of a metal version - Permeable fabric eliminates condensation on the duct surface

Company Details

Employees
14
Address
Pieter Verhaeghestraat 20, Kuurne,vlaanderen 8520,belgium
Industry
Wholesale Building Materials
NAICS
Lumber and Other Construction Materials Merchant Wholesalers
Lumber, Plywood, Millwork, and Wood Panel Merchant Wholesalers
Brick, Stone, and Related Construction Material Merchant Wholesalers
Roofing, Siding, and Insulation Material Merchant Wholesalers
Other Construction Material Merchant Wholesalers
Website
xilio.be
HQ
Kuurne, Vlaanderen
Looking for a particular Prihoda Be-Fr-Ch | Textile Ducting And Diffusers employee's phone or email?

Prihoda Be-Fr-Ch | Textile Ducting And Diffusers Questions

News

Xilio Therapeutics Announces Upcoming Presentations at the - GlobeNewswire

Xilio Therapeutics Announces Upcoming Presentations at the GlobeNewswire

Xilio's second bailout | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Xilio's second bailout | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Xilio turns to Life Science Cares Boston for community collaboration - The Business Journals

Xilio turns to Life Science Cares Boston for community collaboration The Business Journals

Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com

Xilio Therapeutics faces Nasdaq delisting over share price Investing.com

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results GlobeNewswire

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal - Fierce Biotech

AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal Fierce Biotech

AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B - BioSpace

AbbVie Triples Down on T Cell Therapies in Xilio Deal Worth Up to $2.1B BioSpace

AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn - PMLiVE

AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn PMLiVE

Pharma Boom or Bust? Deciphering Xilio Therapeutics’ Steep Stock Movements - timothysykes.com

Pharma Boom or Bust? Deciphering Xilio Therapeutics’ Steep Stock Movements timothysykes.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire

No lost causes at Xilio and Lyell | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

No lost causes at Xilio and Lyell | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Xilio Therapeutics Announces Proposed Public Offering - GlobeNewswire

Xilio Therapeutics Announces Proposed Public Offering GlobeNewswire

ASCO-GI – no masking Xilio's setback | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

ASCO-GI – no masking Xilio's setback | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering - GlobeNewswire

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering GlobeNewswire

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering - GlobeNewswire

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering GlobeNewswire

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - GlobeNewswire

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - GlobeNewswire

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results GlobeNewswire

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - GlobeNewswire

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs GlobeNewswire

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead - GlobeNewswire

Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead GlobeNewswire

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

Xilio Therapeutics, Inc. (XLO) Reports Q2 Loss, Misses Revenue Estimates Yahoo Finance

Xilio gets a Gilead-shaped reprieve | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Xilio gets a Gilead-shaped reprieve | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Xilio Therapeutics Awards $7,400 in Stock Options to Strategic New Employees - Stock Titan

Xilio Therapeutics Awards $7,400 in Stock Options to Strategic New Employees Stock Titan

Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects - Stock Titan

Cancer Drug Breakthrough: Xilio's Vilastobart Delivers Strong Results with Fewer Side Effects Stock Titan

Xilio Therapeutics Lands Major $50M Financing Deal with Potential for $150M Total from Gilead, Elite VCs - Stock Titan

Xilio Therapeutics Lands Major $50M Financing Deal with Potential for $150M Total from Gilead, Elite VCs Stock Titan

Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series - Stock Titan

Immuno-Oncology Biotech Xilio Therapeutics Unveils Complex Public Offering With Multiple Warrant Series Stock Titan

26,000-Share Grant: Xilio Therapeutics Grants Options at $0.8326 Exercise Price - Stock Titan

26,000-Share Grant: Xilio Therapeutics Grants Options at $0.8326 Exercise Price Stock Titan

AbbVie expands oncology R&D with Xilio deal - The Pharma Letter

AbbVie expands oncology R&D with Xilio deal The Pharma Letter

Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count - Fierce Biotech

Gilead pays $43.5M for early-phase IL-12 prospect from Xilio as biotech reduces head count Fierce Biotech

We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely - simplywall.st

We're Hopeful That Xilio Therapeutics (NASDAQ:XLO) Will Use Its Cash Wisely simplywall.st

Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 - BioWorld MedTech

Xilio advances masked T-cell engagers targeting PSMA, CLDN18.2 and STEAP1 BioWorld MedTech

Xilio inks $648M IL-12 deal with Gilead, reprioritizes pipeline - BioWorld MedTech

Xilio inks $648M IL-12 deal with Gilead, reprioritizes pipeline BioWorld MedTech

Why Is Xilio Therapeutics (XLO) Stock up 168% Today? - InvestorPlace

Why Is Xilio Therapeutics (XLO) Stock up 168% Today? InvestorPlace

Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing - Business Wire

Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing Business Wire

Akrevia Rebrands as Xilio Therapeutics, Snags $100 Million in Series B - BioSpace

Akrevia Rebrands as Xilio Therapeutics, Snags $100 Million in Series B BioSpace

Akrevia no more, Xilio Therapeutics bags $101M for I-O programs - Fierce Biotech

Akrevia no more, Xilio Therapeutics bags $101M for I-O programs Fierce Biotech

Top Prihoda Be-Fr-Ch | Textile Ducting And Diffusers Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant